Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
暂无分享,去创建一个
C. Fuchs | J. Tabernero | B. Melichar | H. Safran | J. Zalcberg | D. Ferry | R. Passalacqua | Ling Gao | Y. Hsu | I. Chau | M. Koshiji | G. Aprile | L. Santos | A. Liepa | J. Tomasek | J. Pikiel | C. Yong | Filip Dumitru | C. Goswami | M. Tehfé | E. Topuzov | William Campbell | C. Sivanandan | J. Schwartz | Cho Jae Yong | W. Campbell | L. Gao | Ling Gao
[1] D. Cunningham,et al. COUGAR-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma. , 2013 .
[2] G. Mills,et al. Targeting the hepatocyte growth factor-cMET axis in cancer therapy. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Rebecca C Fitzgerald,et al. A systematic approach to therapeutic target selection in oesophago-gastric cancer , 2012, Gut.
[4] A. Wotherspoon,et al. A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Joon-Oh Park,et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Shah,et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] A. Hinke,et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). , 2011, European journal of cancer.
[8] D. Carbone,et al. Insulin‐like growth factor‐I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45 , 2011, Cancer.
[9] D. Cunningham,et al. Targeting angiogenesis in esophagogastric adenocarcinoma. , 2011, The oncologist.
[10] Tao Li,et al. Sonic Hedgehog Pathway Is Essential for Maintenance of Cancer Stem-Like Cells in Human Gastric Cancer , 2011, PloS one.
[11] A. Jemal,et al. Global Cancer Statistics , 2011 .
[12] C. Heldin,et al. Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-β phosphorylation, and microvessel density in gastric cancer , 2010, BMC Cancer.
[13] Yoon-Koo Kang,et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.
[14] D. Camidge,et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] G. Jayson,et al. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors , 2009, British Journal of Cancer.
[16] Takao Kawabe,et al. Regulation of the hedgehog signaling by the mitogen‐activated protein kinase cascade in gastric cancer , 2009, Molecular carcinogenesis.
[17] K. Shim,et al. The Clinicopathological Significance of Tissue Levels of Hypoxia-Inducible Factor-1α and Vascular Endothelial Growth Factor in Gastric Cancer , 2009, Gut and liver.
[18] Su-jin Kim,et al. Clinicopathologic significance of HIF-1α, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer , 2008, BMC Cancer.
[19] G. Basaran,et al. Vascular Endothelial Growth Factor, Hypoxia-Inducible Factor 1 Alpha and CD34 Expressions in Early-Stage Gastric Tumors: Relationship with Pathological Factors and Prognostic Impact on Survival , 2007, Oncology.
[20] M. Orditura,et al. Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) is an Independent Prognostic Indicator of Worse Outcome in Gastric Cancer Patients , 2007, Annals of Surgical Oncology.
[21] Ji-Feng Wu,et al. Microvessel density is a prognostic marker of human gastric cancer. , 2006, World journal of gastroenterology.
[22] M. Vieth,et al. Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] P. Gong,et al. Relationship between the expression of iNOS,VEGF,tumor angiogenesis and gastric cancer. , 2002, World journal of gastroenterology.
[24] L. Ellis,et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. , 2002, European journal of cancer.
[25] P. Carmeliet,et al. Angiogenesis in cancer and other diseases , 2000, Nature.
[26] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[27] D. Osoba,et al. Interpreting the significance of changes in health-related quality-of-life scores. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[29] David L. DeMets,et al. Asymmetric group sequential boundaries for monitoring clinical trials , 1982 .